Increased serum NfL and GFAP levels indicate different subtypes of neurologic immune‐related adverse events during treatment with immune checkpoint inhibitors DOI Creative Commons
Cynthia L. Schmitt, K. Müller, Steffen Tiedt

et al.

International Journal of Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 20, 2025

Abstract Neurologic immune‐related adverse events (nirAEs) represent rare, yet severe side effects associated with immune checkpoint inhibitor (ICI) therapy. Given the absence of established diagnostic biomarkers for nirAEs, we aimed to evaluate utility serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP). Fifty‐three patients were included at three comprehensive cancer centers, these 20 manifest nirAEs 11 irHypophysitis. Controls without any irAE ( n = 8) other irAEs 14). Using a single‐molecule enzyme‐linked immunosorbent assay (Simoa), levels measured prior to, during after manifestation (n)irAEs in 80 samples. Symptom severity was graded according Common Criteria Adverse Events (CTCAE) version 5.0. Serum NfL significantly higher nirAE group 20) compared irHypophysitis 11; p .0025) controls 22; .0384). Subgroup analysis demonstrated significant elevation peripheral nerves (PNirAE) contrast neuromuscular syndromes (NMirAE) .0260). GFAP highest affecting central nervous system (CNSirAE) PNirAE NMirAE .0064). increased .0069, .0092). Individuals elevated exhibited less favorable outcomes .0199). Measurement may be helpful differentiation broad spectrum serve as an indicator symptom severity. Further investigation is needed their potential prognostic biomarkers.

Language: Английский

Increased serum NfL and GFAP levels indicate different subtypes of neurologic immune‐related adverse events during treatment with immune checkpoint inhibitors DOI Creative Commons
Cynthia L. Schmitt, K. Müller, Steffen Tiedt

et al.

International Journal of Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 20, 2025

Abstract Neurologic immune‐related adverse events (nirAEs) represent rare, yet severe side effects associated with immune checkpoint inhibitor (ICI) therapy. Given the absence of established diagnostic biomarkers for nirAEs, we aimed to evaluate utility serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP). Fifty‐three patients were included at three comprehensive cancer centers, these 20 manifest nirAEs 11 irHypophysitis. Controls without any irAE ( n = 8) other irAEs 14). Using a single‐molecule enzyme‐linked immunosorbent assay (Simoa), levels measured prior to, during after manifestation (n)irAEs in 80 samples. Symptom severity was graded according Common Criteria Adverse Events (CTCAE) version 5.0. Serum NfL significantly higher nirAE group 20) compared irHypophysitis 11; p .0025) controls 22; .0384). Subgroup analysis demonstrated significant elevation peripheral nerves (PNirAE) contrast neuromuscular syndromes (NMirAE) .0260). GFAP highest affecting central nervous system (CNSirAE) PNirAE NMirAE .0064). increased .0069, .0092). Individuals elevated exhibited less favorable outcomes .0199). Measurement may be helpful differentiation broad spectrum serve as an indicator symptom severity. Further investigation is needed their potential prognostic biomarkers.

Language: Английский

Citations

0